Skip to content

Ocular Therapeutix OCUL Cash Flow Statement

FY'25FY'24FY'23FY'22
-$265.94M-37.4%-$193.51M-140%-$80.74M-13.7%-$71.04M-984%
$4.32M+14.2%$3.79M+26.9%$2.98M+41.4%$2.11M-12.9%
$43.18M+30.4%$33.11M+85.7%$17.83M+5.1%$16.96M+13.3%
-$204.88M-52.1%-$134.68M-91.8%-$70.23M-17.8%-$59.6M+9.1%
$12.01M+832%$1.29M-78.8%$6.09M+63.8%$3.72M+211%
-$11.88M-822%-$1.29M+78.8%-$6.09M-63.8%-$3.72M-211%
$561.72M+69.1%$332.11M+95.6%$169.83M+11,580%$1.45M-49.0%
$344.96M$93.51M+251%-$61.86M+3.2%
-$216.89M-59.5%-$135.97M-78.1%-$76.32M-20.5%-$63.32M+5.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Ocular Therapeutix generate?
Ocular Therapeutix (OCUL) generated -$226.2M in operating cash flow over the trailing twelve months.
What is Ocular Therapeutix's free cash flow?
After $14.7M of capital expenditures, Ocular Therapeutix's free cash flow was -$240.9M over the trailing twelve months, down 62.3% year over year.
Where does Ocular Therapeutix's cash flow data come from?
Every line is extracted from Ocular Therapeutix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.